Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 1/20 | 0.47 |
| ▸ | RXRB | P28702 | 1/20 | 0.47 |
| ▸ | RXRG | P48443 | 1/20 | 0.47 |
| ▸ | FFAR4 | Q5NUL3 | 3/20 | 0.46 |
| ▸ | FFAR1 | O14842 | 7/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | MAOB | P27338 | 1/20 | 0.44 |
| ▸ | PTGER1 | P34995 | 4/20 | 0.44 |
| ▸ | PTGER4 | P35408 | 3/20 | 0.44 |
| ▸ | PTGER3 | P43115 | 3/20 | 0.44 |
| ▸ | PTGER2 | P43116 | 3/20 | 0.44 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.43 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7180555 | 0.92 | MRGPRX4 (0.44) | RXRARXRBRXRGFFAR4FFAR1 | |
| SCHEMBL7181193 | 0.92 | FFAR4 (0.45) | RXRARXRBRXRGFFAR4FFAR1 | |
| SCHEMBL7190536 | 0.89 | MRGPRX4 (0.45) | RXRARXRBRXRGFFAR4FFAR1 | |
| SCHEMBL7180798 | 0.87 | FFAR4 (0.44) | RXRARXRBRXRGFFAR4FFAR1 | |
| SCHEMBL7184403 | 0.87 | MRGPRX4 (0.49) | RXRAFFAR1MEN1KMT2AMAOB | |
| SCHEMBL7177020 | 0.86 | HPGD (0.48) | RXRARXRBRXRGFFAR1MEN1 | |
| SCHEMBL7177769 | 0.86 | MAOB (0.48) | RXRARXRBRXRGFFAR4FFAR1 | |
| SCHEMBL7179980 | 0.84 | RXRA (0.46) | RXRAMEN1KMT2AMAOBMRGPRX4 | |
| Lithium SCHEMBL7177776 | 0.83 | MAOB (0.48) | RXRARXRBRXRGFFAR4FFAR1 | |
| SCHEMBL7183556 | 0.83 | MRGPRX4 (0.46) | RXRARXRBFFAR1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6579663-B2 | Chemical intermediates such as lithium 2,6-dimethylbenzoyl phenylphosphine for preparation of acylphosphines, acylphosphine oxides or acylphosphine sulfides | CIBA SPECIALTY CHEMICALS CORPORATION | 2003-06-17 | — | — | US | disclosed |
| US-20020107413-A1 | Organometallic monoacylarylphosphines | WOLF JEAN-PIERRE (CH) | 2002-08-08 | — | — | US | disclosed |
| US-6399805-B2 | SUCH AS LITHIUM 2,6-DIMETHYLBENZOYLPHENYLPHOSPHINE, USE AS PHOTOINITIATORS IN PHOTOCURABLE COMPOSITIONS SUCH AS FOR PHOTOGRAPHIC PRODUCTION OF RELIEF IMAGES | CIBA SPECIALTY CHEMICALS CORPORATION | 2002-06-04 | — | — | US | disclosed |
| US-20010031898-A1 | Organometallic monoacylarylphosphines | CIBA SPECIALTY CHEMICALS CORP. | 2001-10-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020107413-A1 | Organometallic monoacylarylphosphines | CBR1, NAF1, DHCR24 | RXRA 2745/4885RXRB 3027/4885RXRG 2912/4885 |
| US-20010031898-A1 | Organometallic monoacylarylphosphines | NAF1, DHCR24, CBR1 | RXRA 2809/4885RXRB 3240/4885RXRG 2862/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.